Skip to content

Near Patient Molecular Testing in Sepsis

Near Patient Molecular Testing in Sepsis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05469048
Acronym
NEPTUNE
Enrollment
63
Registered
2022-07-21
Start date
2020-03-12
Completion date
2022-10-31
Last updated
2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Systemic Inflammatory Response Syndrome

Brief summary

The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

Detailed description

The ability of SeptiCyte RAPID to differentiate sepsis from infection-negative systemic inflammation will be determined using retrospective physician diagnosis performed by an external panel of three physicians not involved with the care of the patients.

Interventions

None listed

Sponsors

Rush University Medical Center
CollaboratorOTHER
Grady Memorial Hospital
CollaboratorOTHER
University of Southern California
CollaboratorOTHER
Immunexpress
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

1. ≥18 years old on the date of ICU admission 2. Systemic Inflammatory Response Syndrome (SIRS) present, as defined by the presence of two or more of the following: 1. Temperature \> 38°C or \< 36°C 2. Heart Rate \> 90 beat/min 3. Tachypnea \> 20/min or PaCO2 \< 32 mmHg 4. WBC count \> 12 000/mm3 or \< 4 000/mm3 or \> 10% immature neutrophils (bands) 3. Consent to study inclusion, either by patient or legal surrogate before study-related sample processing 4. Study sample collection within 24 hours of ICU admission order

Exclusion criteria

1. Age less than 18 years old on the day of ICU admission 2. No order to admit to ICU 3. Not physically admitted to ICU 4. Commencement of non-prophylactic antibiotics ≥ 24 hours prior to ICU admission 5. Study sample collection \> 24 hours from ICU admission order 6. No clinical cultures or serologic tests obtained when sepsis was suspected 7. Elective cardiac surgery patients with an expected duration in ICU of less than 24 hours 8. Transfer from another ICU where subject was admitted for ≥ 24 hours.

Design outcomes

Primary

MeasureTime frameDescription
Real-time evaluation of the diagnostic accuracy of SeptiCyte RAPID in differentiating sepsis from non-infectious systemic inflammation in patients admitted to the ICU.Time for enrollment, process samples, and collect data, an average of 1 yearPercentage of correctly identified patients with sepsis or non-infectious systemic inflammation using SeptiCyte RAPID compared to clinical assessments using routine clinical, laboratory, and other findings.

Secondary

MeasureTime frameDescription
Comparison of diagnostic accuracy between SeptiCyte RAPID and up to 15 other clinical parameters in differentiating sepsis from non-infectious systemic inflammation in patients admitted to the ICU.Time for enrollment, process samples, and collect data, an average of 1 yearMulti-parametric model to compare diagnostic accuracy between SeptiCyte RAPID alone or in combination with up to 15 other clinical parameters.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026